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ABSTRACT Burkholderia pseudomallei causes the potentially fatal disease melioidosis. It is generally accepted that B. pseudomal-
lei is a noncommensal bacterium and that any culture-positive clinical specimen denotes disease requiring treatment. Over a
23-year study of melioidosis cases in Darwin, Australia, just one patient from 707 survivors has developed persistent asymptom-
atic B. pseudomallei carriage. To better understand the mechanisms behind this unique scenario, we performed whole-genome
analysis of two strains isolated 139 months apart. During this period, B. pseudomallei underwent several adaptive changes. Of 23
point mutations, 78%were nonsynonymous and 43%were predicted to be deleterious to gene function, demonstrating a strong
propensity for positive selection. Notably, a nonsense mutation inactivated the universal stress response sigma factor RpoS, with
pleiotropic implications. The genome underwent substantial reduction, with four deletions in chromosome 2 resulting in the
loss of 221 genes. The deleted loci included genes involved in secondary metabolism, environmental survival, and pathogenesis.
Of 14 indels, 11 occurred in coding regions and 9 resulted in frameshift mutations that dramatically affected predicted gene
products. Disproportionately, four indels affected lipopolysaccharide biosynthesis andmodification. Finally, we identified a
frameshift mutation in both P314 isolates withinwcbR, an important component of the capsular polysaccharide I locus, suggest-
ing virulence attenuation early in infection. Our study illustrates a unique clinical case that contrasts a high-consequence infec-
tious agent with a long-term commensal infection and provides further insights into bacterial evolution within the human host.
IMPORTANCE Some bacterial pathogens establish long-term infections that are difficult or impossible to eradicate with current
treatments. Rapid advances in genome sequencing technologies provide a powerful tool for understanding bacterial persistence
within the human host. Burkholderia pseudomallei is considered a highly pathogenic bacterium because infection is commonly
fatal. Here, we document within-host evolution of B. pseudomallei in a unique case of human infection with ongoing chronic
carriage. Genomic comparison of isolates obtained 139 months (11.5 years) apart showed a strong signal of adaptation within
the human host, including inactivation of virulence and immunogenic factors, and deletion of pathways involved in environ-
mental survival. Two global regulatory genes were mutated in the 139-month isolate, indicating extensive regulatory changes
favoring bacterial persistence. Our study provides insights into B. pseudomallei pathogenesis and, more broadly, identifies paral-
lel evolutionary mechanisms that underlie chronic persistence of all bacterial pathogens.
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Burkholderia pseudomallei is a Gram-negative bacterium thatcauses melioidosis, a potentially fatal infectious disease that is
frequently associated with at-risk individuals but can also cata-
strophically afflict healthy people. Melioidosis is contracted by
percutaneous inoculation, inhalation, ingestion, or aspiration fol-
lowing environmental exposure to soil, water, or aerosols contain-
ing B. pseudomallei (1). Although Southeast Asia and northern
Australia have historically been considered “hot spots” of envi-
ronmental B. pseudomallei presence, this organism is becoming
increasingly recognized as an important cause of morbidity and
mortality in other regions (2). Infection with B. pseudomallei can
be difficult to treat and requires specific and protracted antibiotic
therapy (1).
The clinical picture ofmelioidosis is multifarious, with presen-
tation and outcome determined by a combination of infecting
dose, mode of infection, host risk factors, and yet-to-be-
elucidated bacterial virulence determinants (3). Without a
prompt diagnosis and access to appropriate antibiotics and state-
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of-the-art intensive care facilities, the overall mortality rate is
~40%, increasing to90% in those presenting with septic shock
(1). An ongoing prospective study of melioidosis cases in Darwin,
Australia (3), has documented 815 culture-confirmedmelioidosis
cases since October 1989, of which 108 were fatal (13%). Approx-
imately 85% of these patients presented with acute melioidosis
following a presumed recent infection, 11% displayed chronic ill-
ness (defined as symptoms lasting2months), and the remaining
4% had delayed disease activation following latency (3). In all but
one case, melioidosis survivors (n 707) from the Darwin study
eventually cleared their initial or relapsed B. pseudomallei infec-
tions. This single individual, patient 314 (P314), has remained
chronically colonized with B. pseudomallei since being diagnosed
with melioidosis in 2000.
Previous longitudinal studies of Burkholderia dolosa, Pseu-
domonas aeruginosa, and Staphylococcus aureus isolates obtained
from chronic infections of patients with cystic fibrosis have iden-
tified convergent patterns of evolution that include decreased vir-
ulence, increased antimicrobial resistance, and altered metabolic
fitness due to similar selective pressures (4–8). Additionally, re-
ductive evolution has been observed in a chronic P. aeruginosa
infection (5) and is a common trait among obligate pathogens,
including Burkholderia mallei, Rickettsia spp., Chlamydia spp.,
and Mycobacterium spp. (9–11). These convergent adaptations
suggest that some bacterial pathogens undergo key genetic
changes in vivo during the transition to chronic disease, resulting
in a substantial and sustained niche shift away from being an en-
vironmental organism or acute pathogen. In the present study, we
have applied next-generation whole-genome sequencing (WGS)
technologies to analyze and accurately catalogue genome-wide
alterations between the initial isolate (MSHR1043), a 37-month
isolate (MSHR1655) and a 139-month isolate (MSHR6686) from
P314. Our study of adaptation during chronic persistence sub-
stantially adds to the current knowledge of bacterial evolution
within the human host.
RESULTS AND DISCUSSION
Assembly and genomic features of the initial P314 isolate,
MSHR1043.The Illumina-454 hybrid assembly ofB. pseudomallei
MSHR1043 (GenBank accession no. AOGU00000000) is in 44
high-quality contigs totaling 7,221,181 bp and has a GC content
of 68.1%. Alignment of MSHR1043 Illumina reads with
MSHR1043 resulted in 99.9% of the reads mapping to this as-
sembly. Further contig joining was not possible with these data
because of several large repetitive regions in B. pseudomallei, in-
cluding 16S RNA, tRNA, Hep_Hag motifs, and variable-number
tandem repeat loci. The average size and GC content of the
currently six closed B. pseudomallei genomes (1026b, K96243,
MSHR668, 1710b, BPC006, and 1106a) are 7,178,622 bp and
68.2%, respectively. The estimated size and GC content of
MSHR1043 suggest that this strain has not undergone large ge-
netic changes in vivo.
In contrast, 139-month isolate MSHR6686 exhibits four large
deletions on chromosome 2, which reduce the size of the genome
by 285 kb to ~6.93 Mbp. Thirty-seven-month isolate MSHR1655
is alsomissing three of these four deleted regions, totaling ~245 kb
(see Table S1 in the supplemental material). This observation is
consistent with the reductive evolution of bacterial genomes in
response to a niche shift toward a more restricted and intimate
long-term association with a eukaryotic host (9–11). This phe-
nomenon is similar to that observed in B. mallei, a clonal species
within the B. pseudomallei clade that contains a genome smaller
than its B. pseudomallei ancestor because of the loss of several loci
following its transition from a soil saprophyte to a restricted, pri-
marily equine, niche (9). As expected, assembly of unmapped
reads fromMSHR6686 did not yield additional contigs, indicating
that MSHR6686 has not acquired exogenous DNA. This observa-
tion is consistent with previous in vivo evolution studies using
closed bacterial genomes that have identified large-scale deletions
but not large insertions (5, 12). The lack of MSHR1043 closure
prevented comprehensive characterization of structural variation;
however, alignment of MSHR1043 contigs against closed B. pseu-
domallei genomes failed to identify major deletions or novel in-
versions, suggesting overall colinearity of the genomes. All other
mutations (single-nucleotide polymorphisms [SNPs], small
[15-bp] indels, and deletions) were readily identified.
Genome-wide point mutations between the initial and 139-
month P314 isolates show a strong signal of positive selection.
Twenty-three SNPs between MSHR1043 and MSHR6686 were
identified. Nineteen SNPs caused amino acid sequence altera-
tions, one of which resulted in a nonsense mutation. Ten SNPs
were predicted to have a disruptive effect on the protein product
(Table 1). The strikingly high proportion of nonsynonymous
(NS) mutations in MSHR6686 indicates that the in vivo B. pseu-
domallei population in P314 is under strong positive selection.
This phenomenon has been observed in relapse melioidosis (12)
and in chronic in vivo infections caused by other free-living bac-
teria such as P. aeruginosa (5) and B. dolosa (4).
The single nonsense mutation in MSHR6686 occurred in
D512_11298, resulting in truncation of the sigma factor protein
RpoS (Q82stop). Sigma factors actively recruit RNA polymerase
for upregulated transcription in response to certain environmen-
tal cues. RpoS, the universal stress response sigma factor, upregu-
lates a large array of genes in response to environmental stimuli,
including low pH, oxidative stress, extreme temperatures, and
carbon starvation (13, 14). This single mutation therefore has the
pleiotropic potential to affect a large portion of the organism’s
metabolism. Although the loss of rpoS would be highly disadvan-
tageous for an organism facing a complex natural environment, it
potentially removes a metabolic cost and thus can confer selective
advantages in the host environment. Identified rpoS mutants in
other bacterial species have several selective advantages, including
improved nutrient assimilation under nutrient-limiting condi-
tions (15), abolished transcription of certain genes in stationary
phase and superinduction of other stationary-phase-induced
genes required for host survival (16), increased antibiotic resis-
tance and persistence (17), and biofilm formation (18). Therefore,
rpoS abolition in MSHR6686 probably has relatively minor nega-
tive consequences in vivo.
MSHR6686 also has a predicted deleterious NS mutation
(A660T) in anRpoDprotein (encoded byD512_27123). Although
RpoD is essential for cellular function, MSHR1043 has genes that
encode seven distinct RpoD proteins (D512_07071, D512_11543,
D512_10313, D512_09748, D512_30918, D512_27123, and
D512_30563). This wide array of RpoD-encoding loci in B. pseu-
domallei may enable the bacterium to respond and adapt to
changing ecological niches, ranging from environmental survival
to eukaryotic (e.g., nematode, plant, mammalian) infection. A
null mutation in one RpoD locus is unlikely to be lethal, although
it is expected to adversely affect certain regulatory pathways. The
Price et al.
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rpoD mutation, but not the rpoS mutation, is also present in
B. pseudomallei MSHR1655 (a previously sequenced strain from
P314 isolated 37months afterMSHR1043;GenBank accession no.
AAHR00000000), indicating that the rpoD mutation is stable in
vivo. It remains unknown how these mutations affect global tran-
scription profiles in P314, and is worthy of further study.
The molecular mechanisms underpinning B. pseudomallei re-
sistance to clinically administered -lactam antibiotics are well
documented (19–23). An NS SNP (S72F) in the class A
-lactamase gene penA (Table 1) leads to 8-fold increased resis-
tance to amoxicillin-clavulanate inMSHR6686 (24g/ml) but no
increased resistance to other -lactams, including ceftazidime
(20, 23). This NS SNP is also present in MSHR1655. Both
amoxicillin-clavulanate and ceftazidime, which are commonly
TABLE 1 SNP differences between the initial (MSHR1043) and 139-month (MSHR6686) B. pseudomallei isolates from P314
Location in
MSHR1043
Nucleotide
change
Amino acid
change
Affected gene
in MSHR1043
(K96243) SNP effecta
Mutated in
MSHR1655? Affected protein(s)
Putative protein
function(s)
seq0001
396179
C¡T T194M D512_01885
(BPSL0128)
NS; deleterious No NtrX DNA transcription regulator
seq0001
684105
C¡T A101A D512_03260
(BPSL0430)
S; neutral No Thioesterase Unknown
seq0001
798196
C¡T A8T D512_03780
(BPSL0530)
NS; neutral No HPr kinase, phosphorylase Cell adhesion, virulence
seq0003
154078
A¡G H115R D512_07998
(BPSL1362)
NS; neutral Yes PstB Phosphate uptake
seq0003
331699
T¡C I33V D512_08718
(BPSL1981)
NS; neutral Yes GalU Sugar, LPS metabolism
seq0003
397164
A¡C L47R D512_09003
(BPSL1924)
NS; deleterious No Hypothetical protein Unknown
seq0003
536977
G¡A NAe NA NA No 99 bp upstream of TetR Unknown
seq0003
678249
G¡T R2242L D512_10148
(BPSL1712)
NS; neutral No Syringomycin synthetase Phytopathogenesis
seq0003
719972
T¡C F84L D512_10298
(BPSL1689)
NS; deleterious No Hypothetical protein Unknown
seq0003
720544
G¡A G85S D512_10303
(BPSL1688)
NS; deleterious Yes Hypothetical protein Unknown
seq0003
943033
G¡A Q82stop D512_11298
(BPSL1505)
Nonsense;
deleterious
No RpoS Universal stress response
seq0003
1040609
G¡A G263D D512_11778
(BPSL1413)
NS; deleterious Yes Glucose-6-phosphate
isomerase
Glycolysis,
gluconeogenesis
seq0006
91557
T¡C L279P D512_14441
(BPSL2409)
NS; deleterious Yes ATP binding protein Molecular transport
seq0007
422966
G¡A NA NA NA No NA Unknown
seq0008
15374
G¡C I637M D512_17625
(BPSL3016)
NS; deleterious Yes Seca Membrane transport;
secretion
seq0017
181448
C¡T S97F (S72F)b D512_21859
(BPSS0946)
NS; neutral Yes Class A -lactamase
PenA
-Lactam resistance
seq0020
32593
C¡A F99L D512_23016
(BPSS1260)
NS; neutral No Hypothetical protein Unknown
seq0028
205054
G¡T R458L D512_25718
(BPSS1501)
NS; neutral Noc ClpB Heat shock
seq0028
229189
T¡C H322R D512_25813
(BPSS1520)
NS; neutral Yesd AraC regulator DNA regulation, virulence
seq0028
480279
T¡C D54G D512_26783
(BPSS1698)
NS; deleterious Yes RsrI DNA methylation
seq0028
553993
C¡T A660T D512_27123
(BPSS1755)
NS; deleterious Yes RpoD Primary sigma factor
seq0028
1047356
G¡A NA NA NA No NA Unknown
seq0028
1280562
G¡A S2S D512_30428
(BPSS2321)
S; neutral Yes Hypothetical protein Unknown
a According to SnpEff (66) and PROVEAN (67). S, synonymous. NS, nonsynonymous. NS, not applicable.
b Resides within the previously described, conserved PenA 70SXXK73 motif (68). S72F causes ~4-fold increased resistance to amoxicillin-clavulanic acid but not to other -lactams
(20, 69).
c MSHR1655 possesses a different mutation in this gene (insertion of a repetitive NAP motif at the 3= end).
d MSHR1043 possesses the mutant allele; MSHR1655 and MSHR6686 possess the wild-type allele.
e NA, not applicable.
In Vivo Evolution of B. pseudomallei over 12 Years
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used to treat B. pseudomallei infections, have been administered
on multiple occasions over the period of P314’s infection. How-
ever, unlike ceftazidime, amoxicillin-clavulanate has only been
administered to treat other organisms complicating P314’s bron-
chiectasis. Therefore, the PenA S72F mutant has arisen and per-
sisted in the B. pseudomallei population as a consequence of on-
going selective pressures incurred by semiregular amoxicillin-
clavulanate treatment for other pathogens. Amoxicillin-
clavulanate-resistant B. pseudomallei may potentiate cross-
resistance in other pathogens via either recombination of mutant
penA into other species or as a side effect of localized enzymatic
degradation. The reduced effectiveness of amoxicillin-clavulanate
against other pathogens in the airways of P314 remains to be ex-
plored.
Many of the remaining NS mutations in MSHR6686 occurred
in genes whose functions are not well characterized in B. pseu-
domallei. Four (21%) NS point mutations were identified in hy-
pothetical proteins (encoded by D512_09003, D512_10298,
D512_10303, and D512_23016), three of which were predicted to
be detrimental to protein function (Table 1). Other loss-of-
function NS SNPs were identified in poorly characterized genes
(D512_01885, D512_11778, D512_14441, D512_17625, and
D512_26783). Although the functional role of these genes remains
enigmatic, our study demonstrates that they are all dispensable in
chronic infection and their loss may even be beneficial, either
because these loci elicit a strong immunological response or oth-
erwise have evolutionary costs that select for their inactivation.
Genome-wide indels between P314 isolates demonstrate
strong selective pressure toward loss-of-function mutations. A
previous study of relapse B. pseudomallei isolate pairs found that
only 40% of the indels found occurred in putative coding se-
quences (12). In contrast, 11/14 (79%) small (15-bp) indels (Ta-
ble 2) identified betweenMSHR1043 andMSHR6686 occurred in
putative coding regions. Seven of these coding sequence indels are
also present in MSHR1655. Interestingly, the three intergenic in-
dels occurred exclusively in MSHR1043 and were not observed in
MSHR6686, MSHR1655, or closed B. pseudomallei genomes.
Nine indels in MSHR6686 caused frameshift mutations that al-
tered peptide length, whereas two were in-frame indels (Table 2).
The in-frame indels were predicted to have a neutral impact on
protein function, in contrast to the frameshift mutations, which
were all detrimental. The overrepresentation of indels in coding
regions provides further evidence for positive selection in P314.
MSHR6686 has accumulated four indels affecting lipopolysac-
charide (LPS) biosynthesis and modification loci. LPS is an inte-
gral component of the outer membrane of Gram-negative bacte-
ria and is a known virulence factor in B. pseudomallei that confers
resistance to bactericidal compounds in human serum (24). LPS is
also critical for the successful establishment of acuteB. pseudomal-
lei infection, enabling the bacterium to escapemacrophage killing
in vitro (25). LPS is composed of three components: the
membrane-associated lipid A, the oligosaccharide-rich core, and
the immunogenic outermembraneO antigen. Although LPS is an
important virulence determinant, the potent immunogenicity of
LPS, particularly itsO antigens, appears disadvantageous for long-
term persistence. Loss of function of O-antigen biosynthesis and
modification is a hallmark of chronic P. aeruginosa infection (5)
and may indicate an important strategy employed by B. pseu-
domallei to evade the immune response.
Indel inactivation of the LPS-associated genes wbiI
(D512_15766) and oacA (D512_08953) has been reported in P314
isolates (26, 27), and these indels aremaintained inMSHR6686. A
1-bp insertion in the highly conserved wbiI gene causes loss of
function of an O-antigen biosynthesis pathway, leading to the
characteristic “rough” LPS phenotype (caused by modification,
reduction, or absence of O-antigen chains) and susceptibility to
human serum (26). A coexisting 2-bp insertion in oacA results in
an LPS that putatively reacts to B.mallei LPS-specific monoclonal
antibody (26). B.mallei lacks OacA (26), which is involved in the
modification of O-antigen L-6dTalp residues by acetylation at
their O-4 position (26, 27) and may also methylate the O-2 posi-
tion (26). Inactivation of OacA in MSHR6686 demonstrates a
convergent evolutionary strategy with the host-adapted pathogen
B.mallei.
We identified two additional genes involved in LPS biosynthe-
sis and modification that appear to be affected by indels in
MSHR6686. A 1-bp insertion in the highly conserved wbiH
(D512_15771) gene, situated immediately downstream of wbiI,
was identified inMSHR6686 but not inMSHR1655 (Table 2). The
wbiH mutation potentially results in defunct initiation of
O-antigen subunit assembly (28). A 2-bp deletion inD512_06755
(encodes LPS heptosyltransferase I, involved in LPS inner core
biosynthesis [29]) caused a frameshift in this protein, resulting in
loss of function. Interestingly, the wbiH and D512_06755 indels
are not present in MSHR1655, although MSHR1655 possesses a
novel indel in D512_06755 that results in the insertion of a repet-
itive motif (AHL) at codon 278. This indel is also predicted to
abolish the function of LPS heptosyltransferase I (Table 2), dem-
onstrating that this locus is under heavy selective pressure to ac-
quire loss-of-function mutations. The continued degradation of
LPS biosynthesis and modification pathways indicates that the
wbiI and oacA mutants are insufficient for complete abolition of
O-antigen immunogenicity, leading to continued downregula-
tion by the bacterium for immune evasion. Alternatively, LPS-
associated loci may no longer be under selection in the host envi-
ronment and are therefore subject to genetic drift. Partial deletion
of anO-antigen acetylasewbiA homologue,D512_20407, was also
observed in MSHR6686. Although WbiA is required for 2-O-
acetylation in B. pseudomallei (27), it is unclear what functional
effect the partial deletion of the ostensibly redundantD512_20407
wbiA locus has, if any, on LPS function. Collectively, our study
consolidates previous findings that LPS is dispensable in chronic
bacterial infections (4, 5).
A 1-bp indel in virG (D512_25678 [or BPSS1494 in K96243]),
observed in bothMSHR1655 andMSHR6686, resulted in a frame-
shift that increased protein length from 245 to 854 amino acids
(Table 2). VirG is part of a two-component sensor-regulator sys-
tem for type 6 secretion system cluster 1 (T6SS1) and is essential
for the expression of this cluster (30).B. pseudomallei produces six
T6SS clusters, although only T6SS1 is necessary for virulence in
the hamster and murine models (30, 31). The T6SS1 apparatus is
structurally similar to bacteriophage, injecting bacterial effector
molecules into the host cell cytosol in a contact-dependent man-
ner (32). On the basis of these prior studies, it is likely that the virG
mutation has resulted in the loss of expression of T6SS1, an im-
portant virulence factor in B. pseudomallei.
A loss-of-function indel in the periplasmic multidrug efflux
lipoprotein AmrA (encoded by BPSL1804 in K96243) was seen in
MSHR1043 but not MSHR6686 or MSHR1655. AmrA is part of
the aminoglycoside and macrolide resistance operon AmrAB-
Price et al.
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OprA, which causes the efflux of antibiotics such as gentamicin
and erythromycin from the B. pseudomallei cytoplasm (33). Con-
comitant with defective AmrAB-OprA in MSHR1043, the genta-
micin MIC is just 1 g/ml, whereas the MIC for MSHR6686 is
12 g/ml. In addition, MSHR1043 fails to grow on Ashdown’s
agar, a selectivemedium for B. pseudomallei that contains 4g/ml
gentamicin (34). A neutral NS SNP atD512_25813 was also iden-
tified in MSHR1043 that was not found in MSHR1655,
MSHR6686 (Table 1), or any other publicly available B. pseu-
domallei genome. The exclusivity of these mutations in
MSHR1043 suggests that this strain resides within a lineage dis-
tinct from that ofMSHR1655 orMSHR6686 or, alternatively, that
the MSHR1043 lineage has since become extinct. The coexistence
of multiple lineages in vivo following a clonal inoculation event
has been documented in isolates from P314 (35), other patients
infected with B. pseudomallei (12, 36), and other species (5). WGS
of additional midpoint isolates is needed to confirm the evolu-
tionary scenario.
Large deletions have occurred in the 139-month isolate,
MSHR6686. Large genomic deletions are themost visible result of
the ongoing process of genome decay that occurs as bacteria adapt
to a more restricted niche (5, 9, 12). Reductive evolution involves
the loss of nonessential bacterial genes in the host environment,
including analogous gene products manufactured by the host that
can be exploited by the bacterium (37). Consistent with irrevers-
ible host adaption in P314, MSHR6686 has cumulatively lost
285 kb at four distinct loci. The deletions in MSHR6686 have
reduced its genome size by 4%, to 6.93Mbp, resulting in the loss of
221 and 195 genes relative toMSHR1043 andK96243, respectively
(see Table S1 in the supplemental material). All of the deletions
occur exclusively on chromosome 2, which contains a greater pro-
portion of gene clusters involved in nonessential functions such as
TABLE 2 Indel differences between the initial (MSHR1043) and 139-month (MSHR6686) B. pseudomallei isolates from P314
Location in
MSHR1043 Nucleotide change
Affected gene
in MSHR1043
(K96243)e Indel effect(s)a
Mutated in
MSHR1655? Affected protein
Putative function(s)
of protein
seq0001
105149
CT¡C NAd NA Nob NA Unknown
seq0001
416897
CCGCGACGCCGAG¡C D512_01975
(BPSL0194)
Deletion (LGVA),
codon 20; neutral
No Hypothetical protein Unknown
seq0001
1496938
GGC¡G D512_06755
(BPSL1120)
Frameshift, codon 64;
premature stop
(381-103 aa); deleterious
Noc LPS heptosyltransferase I Biosynthesis, modification
of LPS core
seq0003
131174
CT¡C D512_07898
(BPSL1343)
Frameshift, codon 25;
premature stop
(270-110 aa); deleterious
Yes Hypothetical protein Unknown
seq0003
388954
G¡GGA D512_08953
(BPSL1936)
Frameshift, codon 100;
premature stop
(394-110 aa); deleterious
Yes OacA Biosynthesis, modification
of LPS O antigen
seq0003
537757
AC¡A Not assigned
(BPSL1804)
Frameshift, codon 247 in
MSHR1043; increased length
(399–419 aa); deleterious
Nob AmrA Antibiotic resistance
seq0003
721338
CGCCGGGGCGG¡C D512_10308
(BPSL1687)
Frameshift, codon 85;
premature stop
(213-179 aa); deleterious
Yes Hypothetical protein Unknown
seq0003
1076302
GC¡G D512_11953
(BPSL2093)
Frameshift, codon 43;
premature stop
(96-73 aa); deleterious
Yes Hypothetical protein Unknown
seq0007
181244
C¡CCACTCG D512_15706
(BPSL2660)
Insertion (HS), codon 174
(205–207 aa); neutral
Yes UreE Nitrogen fixation
seq0007
194989
T¡TC D512_15766
(BPSL2672)
Frameshift, codon 272;
premature stop
(637-550 aa); deleterious
Yes WbiI Biosynthesis, modification
of LPS O antigen
seq0007
196460
G¡GC D512_15771
(BPSL2673)
Frameshift, codon 121;
premature stop
(336-141 aa); deleterious
No WbiH Biosynthesis, modification
of LPS O antigen
seq0020
30723
ACGCAT¡A NA NA Nob NA Unknown
seq0024
104413
GCATCGA¡G NA NA Nob NA Unknown
seq0028
195058
A¡AC D512_25678
(BPSS1494)
Frameshift, codon 183;
increased length
(245-854 aa); deleterious
Yes DNA-binding
response regulator
DNA transcription
regulation, virulence
a According to SnpEff (66) and PROVEAN (67). aa, amino acids.
b Indel identified in MSHR1043; neither any other previously sequenced B. pseudomallei strains nor the two latter P314 isolates, MSHR1655 and MSHR6686, share these indels.
c MSHR1655 has an insertion of a repetitive AHL amino acid motif at codon 278 (total length, 384 amino acids).
d NA, not applicable.
e A 2-bp insertion at position 298 of oacA (D512_08953) and a 1-bp insertion at position 815 of wbiI (D512_15766) have been previously identified (25, 26).
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secondary metabolism, environmental survival, and pathogenesis
than does chromosome 1 (38). Several amino acid metabolism
pathways have been deleted from MSHR6686 (see Table S1), in-
dicating that analogous products exist in the host and are being
utilized by the bacterium in vivo or that these biosynthesis path-
ways are redundant in B. pseudomallei. For example, amino acid
biosynthesis genes are frequently decayed or lost in obligate intra-
cellular human pathogens such as the Rickettsia spp., Chlamydia
spp., and Mycobacterium spp. The loss of these genes therefore
probably provides a metabolic advantage in the P314 B. pseu-
domallei population, enabling a larger proportion of its genome to
be committed to central functions such as replication, transcrip-
tion, and translation (10).
Reductive evolution is also starkly evident in B. mallei, which
has a genome that is ~1.5 Mbp smaller than that of its free-living
ancestor B. pseudomallei. Interestingly, there is substantial parallel
gene loss between MSHR6686 and B. mallei; ~141 kb (49.5%) of
the loci absent from MSHR6686 are also absent from B. mallei,
spanning (in K96243) BPSS1096 to BPSS1112 and BPSS1123 to
BPSS1203 (see Table S1). These deleted loci encode mainly puta-
tive secondary metabolic pathways that facilitate bacterial re-
sponses to different environmental conditions but not those en-
countered in the mammalian host. The absence of these loci in
both B. mallei and the P314-adapted B. pseudomallei strain pro-
vides further insights into the divergence of B. mallei from its
B. pseudomallei ancestor (9).
MSHR6686 has also shed genes encoding putative lipoprotein
capsule biosynthesis and modification, chemotaxis, motility and
quorum sensing, fatty acid biosynthesis, DNA methylation, thia-
mine biosynthesis, antibiotic resistance, and virulence factor bio-
synthesis (see Table S1 in the supplemental material). Many of
these loci are not well characterized in B. pseudomallei, and several
do not yet have known functions. However, two key loci deleted
fromMSHR6686 have previously been functionally characterized.
The first is an efflux pump encoded by the BpeEF-OprC operon
(D512_20002 to D512_20022) that causes the efflux of chloram-
phenicol and trimethoprim (39); the MSHR6686 mutation has
likely rendered this isolate susceptible to these compounds.
Trimethoprim-sulfamethoxazole is an antibiotic frequently used
in melioidosis treatment, although it has not been routinely ad-
ministered to P314 because of the patient’s intolerance to this
drug. Other putative antibiotic resistance genes, including the
BpeGH-OprD operon (D512_22681 to D512_22696) (40) and a
metallo--lactamase gene, D512_31289, were also deleted, al-
though their substrates and functions remain elusive. Efflux pump
mutations have also been observed in a long-term infection with
P. aeruginosa, which, like B. pseudomallei, is naturally resistant to
many antibiotics (5). Characterization of these antibiotic-
resistant loci may provide novel therapeutic options for P314.
The second previously characterized locus abolished in
MSHR6686 is the type III secretion 3 (Bsa TTSS3) virulence clus-
ter. TTSS apparatus are common in Gram-negative pathogens
and have phenotypic features in common with bacterial flagella.
TTSSs allow pathogens to directly inject eukaryotic host cells with
virulence proteins that are functionally similar to host proteins yet
subvert the host cell solely for the benefit of the bacterium (41).
B. pseudomallei produces three TTSS apparatus. Unlike TTSS1
and TTSS2, Bsa TTSS3 is essential for virulence in the hamster
model (42), facilitating invasion of nonphagocytic cells and sub-
sequent vacuolar escape (43). Althoughmany of the genes encod-
ing TTSS3 effector molecules (e.g., bopA, bopE, bapA, and bapC)
are not mutated in MSHR6686, structural components that form
the critical “injectisome” of Bsa TTSS3 are deleted (see Table S1 in
the supplemental material). Previous work has shown that the
deletion of individual TTSS3 effector molecules may not reduce
virulence; however, deletion of the highly conserved gene sctU3
(spaS; D512_25888), which encodes a protein essential to the
TTSS3 secretory pathway and which is also deleted from
MSHR6686, significantly attenuates virulence (42). TTSS appara-
tus show signs of convergent evolution, being downregulated in
vivo in other pathogenic species (5, 44); a notable exception is
B. mallei, which has a fully functional Bsa TTSS3 locus that con-
tributes to its virulence (45). Collectively, our results suggest that
TTSS3 is important during initial infection and maintenance of
virulence capacity but is disadvantageous for long-term commen-
sal B. pseudomallei infection.
Large deletions have been reported in free-living bacterial spe-
cies isolated from chronic infections. Comparison of P. aeruginosa
isolates obtained 96 months apart from a cystic fibrosis patient
revealed a large 188-kb deletion in the latter isolate, with a con-
comitant loss of ~139 genes (5). Similarly, a study of initial and
relapse melioidosis isolate pairs revealed a 330-kb deletion be-
tween two B. pseudomallei isolates (1258a and 1258b) obtained
6 months apart (12). Surprisingly, this deletion affected genes
BPSS1249 to BPSS1483 (232 genes, 10% of the replicon) located
on chromosome 2 yet did not overlap any deleted loci in
MSHR6686 (see Table S1 in the supplemental material). There
was also no overlap in SNPs or indels, with the exception of
BPSS0291 (D512_20007 in MSHR1043), which encodes a lipase-
like protein that was deleted from MSHR6686 and contained a
frameshift in 354e, a lung isolate obtained 75 months after the
original isolate (354a) (12). In general, there was a better correla-
tion between mutations observed in MSHR6686 and those from
chronic infections with other pathogenic species (e.g., P. aerugi-
nosa [5] and Burkholderia cenocepacia [44]) than from relapsed
B. pseudomallei infections (12). Relapsemelioidosis usually results
from inadequate duration of or poor patient compliance with the
prescribed therapy, and is defined as a recurrent clinical illness
after the date for completion of the prescribed treatment for the
initial infection (3, 46, 47). Thus, intact virulence capabilities are a
necessity. The basis for these two different disease pathologies
suggests fundamental selection differences and evolutionary tra-
jectories.
Altered growth rate and morphological differences between
MSHR1043 andMSHR6686.We observed that MSHR6686 takes
approximately 1 to 2 days longer to grow than MSHR1043 when
plated on both rich and selective media, including chocolate agar,
Luria-Bertani agar, and Ashdown’s agar (without gentamicin)
(Fig. 1). Growth rate and morphology differences have also been
observed in other chronically infecting pathogens, including
S. aureus and P. aeruginosa (7, 48). Intriguingly, B. mallei can be
differentiated from wild-type B. pseudomallei on the basis of a
slower growth rate on both minimal and rich media (49). These
parallels suggest that the large deletions observed in MSHR6686,
rather than SNPs or indels accumulated in this strain, are respon-
sible for slower growth.
Cause of avirulence in the initial P314 strain, MSHR1043.
MSHR1043 is avirulent in the intraperitonealmurinemodel, even
at a high infecting dose (A. Tuanyok, unpublished data). We were
therefore interested in identifying the potential molecular basis of
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virulence attenuation in MSHR1043. The Prokaryotic Genome
Automatic Annotation Pipeline used for MSHR1043 annotation
identified 13 frameshift indels in this strain, of which 4 also oc-
curred inMSHR6686 andMSHR1655 (Table 3).Only one of these
indels causes loss-of-function of an essential virulence factor,
WcbR, a fatty acid synthase within the 35-kb capsular polysaccha-
ride I (CPS-I) cluster (50). Intact CPS-I prevents phagocytosis by
host immune cells (51) and is functional in B.mallei (52). In vitro
knockouts of wcbR have a demonstrated reduction in CPS-I pro-
duction and expression (50). The 1-bp indel inwcbR has persisted
throughout P314’s infection (see Figure S1 in the supplemental
material), indicating that it occurred prior to MSHR1043 isola-
tion andhas favorable consequences in vivo.We speculate that this
CPS-I mutation was responsible for virulence attenuation early in
P314’s infection and was a critical step in the progression to
chronic-carriage disease.
In conclusion, we have characterized genome-wide changes
occurring in B. pseudomallei during an ongoing chronic-carriage
infection of the human respiratory tract. The mutational pattern
demonstrates a predominantly positive selection signal that con-
veys benefits for host adaptation and commensalism. The slow
growth rate of chronically infecting bacteria, their exquisite ability
to evade killing by antibiotics and the immune system, and the
inherent heterogeneity of chronic in vivo populations make erad-
ication on the basis of current treatments difficult, if not impossi-
ble. P314’s infection represents a hitherto undescribed B. pseu-
domallei scenario in the global melioidosis literature that we have
termed “chronic carriage” to denote a long-term, persistent hu-
man infection that has become, paradoxically, asymptomatic. Al-
though asymptomatic carriage of B. pseudomallei has been sus-
pected in goats (53), it has been conventionally believed that the
organism is not carried asymptomatically by humans and that any
culture-positive clinical specimen necessarily represents disease
requiring therapy (54). Protracted carriage of B. pseudomallei has
also been observed in some cystic fibrosis patients (55, 56), sug-
gesting that B. pseudomallei commensalism may be more com-
mon than previously thought.
MATERIALS AND METHODS
Ethics statement. This study has been approved by the Human Research
Ethics Committee of the Northern Territory Department of Health and
Menzies School of Health Research, approval numberHREC 02/38 (Clin-
ical and Epidemiological Features ofMelioidosis).Written informed con-
sent was provided by the study participant.
Clinical history of P314 and bacterial isolates used in this study.
P314 is a white female with bilateral non-cystic fibrosis bronchiectasis but
no other melioidosis risk factors who originally presented with a chronic
cough productive of green sputum in July 2000 when 61 years old. P314
had previously been treated for Mycobacterium avium complex and P.
aeruginosa pulmonary infections and had prior surgery for chronic sinus-
itis. A chest X-ray showed patchy pulmonary infiltrates associated with
bilateral basal bronchiectasis, and a computed tomography scan showed
extensive cystic bronchiectasis of the left lower lobe. B. pseudomallei was
cultured from sputum (MSHR1043) and nose and throat swabs at that
time (57). P314’s symptoms initially improved after 14 days of intrave-
nous ceftazidime, but her sputum remained B. pseudomallei positive.
P314 was subsequently given intravenous meropenem for a week, fol-
lowed by 3 weeks of intravenous ceftazidime. Because of a severe
trimethoprim-sulfamethoxazole allergy, P314 was administered doxycy-
cline for the oral “eradication phase” of therapy, which is standard for
melioidosis treatment completion (1).
P314 has subsequently had numerous courses of intravenous ceftazi-
dime and meropenem, trials of nebulized ceftazidime, and prolonged
courses of oral doxycycline and amoxicillin-clavulanate to treat periods of
increased cough and sputum production. In hindsight, these exacerba-
tions and even the initial melioidosis presentation may not have reflected
disease due to B. pseudomallei infection but rather standard bacterial in-
fective exacerbations of bronchiectasis. In August 2003, 37 months after
MSHR1043was isolated, P314 underwent surgical lobectomy of the lower
left lung lobe. B. pseudomallei was cultured from this lung tissue
(MSHR1655). Despite excellent recovery, P314 continued to have respi-
ratory exacerbations that were persistently culture positive for B. pseu-
domallei. In recent years, P314’s respiratory symptoms have improved,
FIG 1 Growth rate and morphology differences between P314 B. pseudomal-
lei isolates. The initial isolate, MSHR1043, grows well after 48 and 72 h of
incubation on selective Ashdown’s agar (without gentamicin) (top and bot-
tom left, respectively). In contrast, the 139-month isolate, MSHR6686, exhib-
its a substantially slower growth rate andmorphological differences that make
it difficult to recognize as B. pseudomallei (48 and 72 h of growth, top and
bottom right, respectively). The growth rate difference is likely due to consid-
erable genetic loss affecting 221 genes on chromosome 2.
TABLE 3 Frameshift indels in P314 isolates MSHR1043, MSHR1655, and MSHR6686 not found in closed or draft genome-sequenced
B. pseudomallei genomes
Protein Gene (K96243) Contig Start End
Type I polyketide synthase WcbR BPSL2789 seq0007 325993 333551
Bbp50 integrase NAa seq0028 553262 553702
Integrase NA seq0028 987262 988081
Aromatic amino acid aminotransferase BPSS2200 seq0028 1122114 1123340
a NA, not applicable.
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although a productive cough with yellow or green sputum persists.
MSHR6686 was isolated in January 2012 (139 months [11.5 years] after
MSHR1043) during a routine visit for bronchiectasis management. P314
has since not been administered antibiotics with activity against B. pseu-
domallei and has reported being the least symptomatic since her initial
melioidosis diagnosis. P314’s sputum remained B. pseudomallei positive
as of January 2013.
MSHR1043 and MSHR6686 were isolated from P314’s sputum sam-
ples by direct plating on chocolate agar. Cultures were screened against
the TTS1 assay (58) to confirm their identity as B. pseudomallei prior to
WGS.
Antimicrobial testing. Etests (bioMérieux, Baulkham Hills, NSW,
Australia) were used to determine the MICs of ceftazidime, gentamicin,
and amoxicillin-clavulanate for P314’s isolates. Etesting was carried out
according to the manufacturer’s instructions.
WGS and hybrid assembly. High-quality and high-yield genomic
DNA was obtained from B. pseudomallei cultures of MSHR1043 and
MSHR6686 as previously described (59). The strains underwent paired-
end WGS (500-bp fragments with ~800 and ~100 coverage, respec-
tively) using the Illumina Genome Analyzer IIx platform (Illumina Inc.,
San Diego, CA). MSHR1043 was also sequenced using the 454 Genome
Sequencer FLX instrument (454 Life Sciences, Branford, CT). Mira 3.4.0
(60) was used to perform de novo hybrid 454-Illumina assembly of
MSHR1043. MSHR1043 Illumina reads were reduced to ~80 coverage
by quality filtering with FASTX-Toolkit v0.0.13 (http://hannonlab.cshl
.edu/fastx_toolkit/) prior toMIRA assembly. 454 and Illumina reads were
quality filtered by MIRA as part of the hybrid assembly process.
The raw hybrid MSHR1043 assembly was subjected to manual contig
assembly to improve draft quality. Gap5 v1.2.11 (61) was used to check
and, where possible, stitch MSHR1043 MIRA-generated contigs. A sec-
ond hybrid assembly was performed using the MIRA-assembled contigs
as a scaffold for unfiltered Illumina reads inVelvet v1.1.04 (62). Regions of
synteny between MSHR1043 and publicly available B. pseudomallei ge-
nomes were then identified using progressiveMAUVE (v2.3.1) alignment
(63), BLAST (64), and the SynMap module of CoGe (http:
//genomevolution.org/CoGe/SynMap.pl). These tools enabled stitching
of additional contigs in nonrepetitive, conserved loci. B. pseudomallei
MSHR1655, which was isolated from P314 37 months after MSHR1043,
was used as a reference. All contig stitches were rigorously validated by
aligning unfiltered Illumina reads with the MSHR1043 reference using
Burrows-Wheeler Aligner (BWA) v0.5.9 (65) with manual verification of
correct read mapping and pairing over the putative contig joins. Variant
calling was performed using the Genome Analysis Toolkit (GATK)
v2.1-11 (66). All SNPs and indels were corrected, and incorrectly assem-
bled contigs were manually separated. This process was iterated until no
SNPs, indels, or misassemblies were identified in MSHR1043 with BWA
and the GATK. To verify the length ofMSHR1043, filtered Illumina reads
were realigned with the reference with subsequent assembly of unaligned
reads using MIRA. Lastly, contigs800 bp in size were discarded.
SNP, indel, and deletion detection and characterization. BWA was
used to align Illumina reads forMSHR6686 against theMSHR1043 refer-
ence genome on the basis of default parameters for paired-end Illumina
data. TheGATKand SAMtools v0.1.18 (67)were subsequently used to call
SNPs and small indels (15 bp) following the removal of duplicate reads
with Picard MarkDuplicates v1.6 (http://picard.sourceforge.net) and
Smith-Waterman realignment of the bam file around regions with a high
mismatch rate according to the GATK. SNPs and indels were restricted to
haploid calls (using the ploidy filter) and filtered for quality using the
GATK with the following parameters for SNPs and indels: clusterSize, 3;
clusterWindowSize, 10; MLEAF,0.95; QD,10.0; MQ,30; FS,20;
QUAL, 30; DP, (average genome coverage)/4 or (average genome
coverage) 3. Larger deletions were detected in MSHR6686 by using the
coverageBed utility of BEDTools v2.15.0 (68) on the basis of a 1-kb win-
dow size. To detect the acquisition of exogenous DNA in MSHR6686,
Illumina reads for MSHR6686 were aligned against MSHR1043 and as-
sembly was performed with unaligned reads using MIRA. All mutations
were visually verified on the basis of Illumina read mapping in Tablet
v1.12.08.29 (69). Two indels in seq0003 388954 (affecting oacA) and
seq0007 194989 (affecting wbiI) have been previously characterized by
dideoxy chain termination sequencing (26) and were confidently identi-
fied by our pipeline. Annotation of variants was performed by using
SnpEff v3.1 (70) with manual BLAST verification against the NCBI Mi-
crobes genome database. Functional characterization of SNPs was carried
out using PROVEAN v1.1 (71).
Nucleotide sequence accession number. This Whole Genome Shot-
gun project has been deposited atDDBJ/EMBL/GenBank under accession
no. AOGU00000000. The version described in this paper is the first ver-
sion, AOGU01000000.
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